Open-Label LILAC-2 Data Demonstrates Trofinetide’s Long-Term Treatment Benefit in Rett Syndrome
7 Dec 2023
https://www.neurologylive.com/view/open-label-lilac-2-data-demonstrates-trofinetide-treatment-benefit-32-months
"New open-label data from the LILAC-2 study ...demonstrated the long-term treatment impacts of trofinetide (Daybue; Acadia Pharmacueticals) in patients with Rett syndrome. All told, patients showed continued improved symptoms for up to 32 months, with no new safety signals observed.'
Open-Label LILAC-2 Data Demonstrates Trofinetide’s Long-Term...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.34 |
Change
1.140(5.64%) |
Mkt cap ! $2.725B | |||
| Open | High | Low | Value | Volume |
| $20.30 | $21.65 | $20.11 | $14.34M | 673.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 633 | $21.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.34 | 2000 | 2 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.37 |
Change
1.140 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $20.26 | $21.64 | $20.19 | 136487 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| NEU (ASX) Chart |